TriangleLABELS · 296db0e8-af6e-4053-874d-2a7c8f7aba50
Prilosec
Open original source → · Download preserved record
Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.
- Label effective date
- 2024-03-19
- Captured
- 2026-09-09T23:37:42.544548+00:00
- Current indication reconciliation
- Not reconciled
Indications and usage: exact source text
- 1 INDICATIONS AND USAGE PRILOSEC is a proton pump inhibitor (PPI) indicated for the: • Treatment of active duodenal ulcer in adults ( 1.1 ) • Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults ( 1.2 ) • Treatment of active benign gastric ulcer in adults ( 1.3 ) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 1 year of age and older ( 1.4 ) • Treatment of erosive esophagitis (EE) due to acid-mediated GERD in patients 1 month of age and older ( 1.5 ) • Maintenance of healing of EE due to acid-mediated GERD in patients 1 year of age and older ( 1.6 ) • Pathologic hypersecretory conditions in adults ( 1.7 ) 1.1 Treatment of Active Duodenal Ulcer PRILOSEC is indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy PRILOSEC in combination with clarithromycin and amoxicillin, is indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy PRILOSEC in combination with clarithromycin is indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, PRILOSEC with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology ( 12.4 ) and the clarithromycin prescribing information, Microbiology section ] . 1.3 Treatment of Active Benign Gastric Ulcer PRILOSEC is indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer in adults. 1.4 Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD) PRILOSEC is indicated for the treatment of heartburn and other symptoms associated with GERD for up to 4 weeks in patients 1 year of age and older. 1.5 Treatment of Erosive Esophagitis (EE) Due to Acid-Mediated GERD Pediatric Patients 1 Year of Age to Adults PRILOSEC is indicated for the short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD that has been diagnosed by endoscopy in patients 1 year of age and older. The efficacy of PRILOSEC used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of PRILOSEC may be considered. Pediatric Patients 1 Month to Less than 1 Year of Age PRILOSEC is indicated for the short-term treatment (up to 6 weeks) of EE due to acid-mediated GERD in pediatric patients 1 month to less than 1 year of age. 1.6 Maintenance of Healing of EE Due to Acid-Mediated GERD PRILOSEC is indicated for the maintenance healing of EE due to acid-mediated GERD in patients 1 year of age and older. Controlled studies do not extend beyond 12 months. 1.7 Pathological Hypersecretory Conditions PRILOSEC is indicated for the long-term treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis) in adults.
Full extracted label fields
- application numbers
- NDA022056
- boxed warning exact
- brand names
- Prilosec
- current indication status
- not_reconciled
- dailymed set url
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6761f84-53ac-4745-a8c8-1e5427d7e179
- generic names
- OMEPRAZOLE MAGNESIUM
- id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- indications and usage exact
- 1 INDICATIONS AND USAGE PRILOSEC is a proton pump inhibitor (PPI) indicated for the: • Treatment of active duodenal ulcer in adults ( 1.1 ) • Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults ( 1.2 ) • Treatment of active benign gastric ulcer in adults ( 1.3 ) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 1 year of age and older ( 1.4 ) • Treatment of erosive esophagitis (EE) due to acid-mediated GERD in patients 1 month of age and older ( 1.5 ) • Maintenance of healing of EE due to acid-mediated GERD in patients 1 year of age and older ( 1.6 ) • Pathologic hypersecretory conditions in adults ( 1.7 ) 1.1 Treatment of Active Duodenal Ulcer PRILOSEC is indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy PRILOSEC in combination with clarithromycin and amoxicillin, is indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy PRILOSEC in combination with clarithromycin is indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, PRILOSEC with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology ( 12.4 ) and the clarithromycin prescribing information, Microbiology section ] . 1.3 Treatment of Active Benign Gastric Ulcer PRILOSEC is indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer in adults. 1.4 Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD) PRILOSEC is indicated for the treatment of heartburn and other symptoms associated with GERD for up to 4 weeks in patients 1 year of age and older. 1.5 Treatment of Erosive Esophagitis (EE) Due to Acid-Mediated GERD Pediatric Patients 1 Year of Age to Adults PRILOSEC is indicated for the short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD that has been diagnosed by endoscopy in patients 1 year of age and older. The efficacy of PRILOSEC used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of PRILOSEC may be considered. Pediatric Patients 1 Month to Less than 1 Year of Age PRILOSEC is indicated for the short-term treatment (up to 6 weeks) of EE due to acid-mediated GERD in pediatric patients 1 month to less than 1 year of age. 1.6 Maintenance of Healing of EE Due to Acid-Mediated GERD PRILOSEC is indicated for the maintenance healing of EE due to acid-mediated GERD in patients 1 year of age and older. Controlled studies do not extend beyond 12 months. 1.7 Pathological Hypersecretory Conditions PRILOSEC is indicated for the long-term treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis) in adults.
- indications and usage tables exact
- is original packager
- true
- manufacturer names
- Covis Pharma US, Inc
- matched search terms
- mastocytosis
- package ndcs
- 70515-625-01
- 70515-610-01
- product ndcs
- 70515-610
- 70515-625
- product types
- HUMAN PRESCRIPTION DRUG
- recent major changes exact
- record type
- complete_spl_indications_section_candidate
- routes
- ORAL
- rxcuis
- 797058
- 797061
- 797063
- 797065
- source batch
- file
- /private/tmp/cancer-full-research/indications/raw/labels-00100.json
- meta
- disclaimer
- Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
- last updated
- 2026-09-09
- results
- limit
- 100
- skip
- 100
- total
- 830
- sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22296db0e8-af6e-4053-874d-2a7c8f7aba50%22
- spl effective date
- 2024-03-19
- spl effective time
- 20240319
- spl set id
- b6761f84-53ac-4745-a8c8-1e5427d7e179
- spl version
- 8
- substance names
- OMEPRAZOLE MAGNESIUM
- uniis
- 426QFE7XLK
- verification flags
- oncology_keyword_candidate_not_clinically_classified
- spl_text_not_verified_identical_to_latest_approved_label
- individual_indications_not_split_or_reconciled
Drugs@FDA application source records
- application number
- NDA022056
- payload
- all indexed label documents
- Appl No
- 022056
- Application Docs Date
- 2008-03-24 00:00:00
- Application Docs ID
- 16851
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022056lbl.pdf
- Submission No
- 1
- Submission Type
- ORIG
- Appl No
- 022056
- Application Docs Date
- 2008-12-04 00:00:00
- Application Docs ID
- 16852
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022056s001019810s087lbl.pdf
- Submission No
- 1
- Submission Type
- SUPPL
- Appl No
- 022056
- Application Docs Date
- 2010-09-10 00:00:00
- Application Docs ID
- 16853
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s090,022056s005lbl.pdf
- Submission No
- 5
- Submission Type
- SUPPL
- Appl No
- 022056
- Application Docs Date
- 2012-02-06 00:00:00
- Application Docs ID
- 16854
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019810s094,022056s010lbledt.pdf
- Submission No
- 10
- Submission Type
- SUPPL
- Appl No
- 022056
- Application Docs Date
- 2012-10-12 00:00:00
- Application Docs ID
- 16855
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019810s095,022056s011lbl.pdf
- Submission No
- 11
- Submission Type
- SUPPL
- Appl No
- 022056
- Application Docs Date
- 2012-10-01 00:00:00
- Application Docs ID
- 16856
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019810s096lbl.pdf
- Submission No
- 12
- Submission Type
- SUPPL
- Appl No
- 022056
- Application Docs Date
- 2014-04-01 00:00:00
- Application Docs ID
- 16857
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019810s098,022056s014lbl.pdf
- Submission No
- 14
- Submission Type
- SUPPL
- Appl No
- 022056
- Application Docs Date
- 2014-02-27 00:00:00
- Application Docs ID
- 16858
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019810s099,022056s015lbl.pdf
- Submission No
- 15
- Submission Type
- SUPPL
- Appl No
- 022056
- Application Docs Date
- 2010-03-05 00:00:00
- Application Docs ID
- 38149
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
- Submission No
- 3
- Submission Type
- SUPPL
- Appl No
- 022056
- Application Docs Date
- 2011-07-06 00:00:00
- Application Docs ID
- 38150
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022056s007,019810s091lbl.pdf
- Submission No
- 7
- Submission Type
- SUPPL
- Appl No
- 022056
- Application Docs Date
- 2011-01-24 00:00:00
- Application Docs ID
- 38151
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019810s092,022056s008lbl.pdf
- Submission No
- 8
- Submission Type
- SUPPL
- Appl No
- 022056
- Application Docs Date
- 2011-05-25 00:00:00
- Application Docs ID
- 38152
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019810s093,022056s009lbl.pdf
- Submission No
- 9
- Submission Type
- SUPPL
- all submission records
- Appl No
- 022056
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 26
- Submission Status
- AP
- Submission Status Date
- 2023-07-18 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 022056
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 25
- Submission Status
- AP
- Submission Status Date
- 2022-03-04 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 022056
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 23
- Submission Status
- AP
- Submission Status Date
- 2020-11-27 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 022056
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 22
- Submission Status
- AP
- Submission Status Date
- 2018-06-07 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 022056
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 21
- Submission Status
- AP
- Submission Status Date
- 2018-08-21 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 022056
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 20
- Submission Status
- AP
- Submission Status Date
- 2016-10-24 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 022056
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 19
- Submission Status
- AP
- Submission Status Date
- 2016-12-19 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 022056
- Review Priority
- STANDARD
- Submission Class Code ID
- 2
- Submission No
- 18
- Submission Status
- AP
- Submission Status Date
- 2016-02-03 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 022056
- Review Priority
- 901 REQUIRED
- Submission Class Code ID
- 3
- Submission No
- 17
- Submission Status
- AP
- Submission Status Date
- 2014-12-19 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 022056
- Review Priority
- 901 REQUIRED
- Submission Class Code ID
- 3
- Submission No
- 15
- Submission Status
- AP
- Submission Status Date
- 2014-02-25 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 022056
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 14
- Submission Status
- AP
- Submission Status Date
- 2014-03-27 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 022056
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 13
- Submission Status
- AP
- Submission Status Date
- 2013-05-15 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- application number
- NDA022056
- approval interpretation
- Application linkage and approved submission are not indication-level current approval verification
- current indication status
- not_reconciled
- drugsfda url
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022056
- has approved submission record
- true
- latest approved submission date
- 2023-07-18
- latest label selection rule
- max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
- latest posted label documents
- Appl No
- 022056
- Application Docs Date
- 2023-07-20 00:00:00
- Application Docs ID
- 74817
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022056s026lbl.pdf
- Submission No
- 26
- Submission Type
- SUPPL
- official application record
- Appl No
- 022056
- Appl Public Notes
- Appl Type
- NDA
- Sponsor Name
- AZURITY
- openfda application present
- true
- products
- Active Ingredient
- OMEPRAZOLE MAGNESIUM
- Appl No
- 022056
- Drug Name
- PRILOSEC
- Form
- FOR SUSPENSION, DELAYED RELEASE;ORAL
- Product No
- 001
- Reference Drug
- 1
- Reference Standard
- 0
- Strength
- EQ 2.5MG BASE/PACKET
- marketing status
- Prescription
- Active Ingredient
- OMEPRAZOLE MAGNESIUM
- Appl No
- 022056
- Drug Name
- PRILOSEC
- Form
- FOR SUSPENSION, DELAYED RELEASE;ORAL
- Product No
- 002
- Reference Drug
- 1
- Reference Standard
- 1
- Strength
- EQ 10MG BASE/PACKET
- marketing status
- Prescription
Source passages and status connections
Passage 1 · indication intro context
- application numbers
- NDA022056
- brand names
- Prilosec
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- incomplete_colon_led_indication_intro
- clinical review status
- pending
- content role
- indication_intro_context
- context span
- end
- 284
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE PRILOSEC is a proton pump inhibitor (PPI) indicated for the: • Treatment of active duodenal ulcer in adults ( 1.1 ) • Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults ( 1.2 ) • Treatment of active benign gastric ulce
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 0
- current approval status
- not_reconciled
- duplicate text group
- dup-f417635124754cfdc21a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OMEPRAZOLE MAGNESIUM
- id
- ind-span-546a137e9ba267255295
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- positive predicate support span
- end
- 75
- end exclusive
- true
- exact text
- is a proton pump inhibitor (PPI) indicated
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 33
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 84
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE PRILOSEC is a proton pump inhibitor (PPI) indicated for the:
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 0
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22296db0e8-af6e-4053-874d-2a7c8f7aba50%22
- spl effective date
- 2024-03-19
- spl set id
- b6761f84-53ac-4745-a8c8-1e5427d7e179
- spl version
- 8
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 2 · positive indication candidate
- application numbers
- NDA022056
- brand names
- Prilosec
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 339
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE PRILOSEC is a proton pump inhibitor (PPI) indicated for the: • Treatment of active duodenal ulcer in adults ( 1.1 ) • Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults ( 1.2 ) • Treatment of active benign gastric ulcer in adults ( 1.3 ) • Treatment of symptomatic gastroes
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 0
- current approval status
- not_reconciled
- duplicate text group
- dup-385dcc196851c5ccb060
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OMEPRAZOLE MAGNESIUM
- id
- ind-span-89668c70a360c360632b
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- positive predicate support span
- end
- 75
- end exclusive
- true
- exact text
- is a proton pump inhibitor (PPI) indicated
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 33
- qualifier mentions
- context exact
- • Treatment of active duodenal ulcer in adults ( 1.1 )
- kind
- age
- polarity
- not_inferred
- span
- end
- 131
- end exclusive
- true
- exact text
- adults
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 125
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 139
- end exclusive
- true
- exact text
- • Treatment of active duodenal ulcer in adults ( 1.1 )
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 85
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22296db0e8-af6e-4053-874d-2a7c8f7aba50%22
- spl effective date
- 2024-03-19
- spl set id
- b6761f84-53ac-4745-a8c8-1e5427d7e179
- spl version
- 8
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 3 · risk or warning
- application numbers
- NDA022056
- brand names
- Prilosec
- classification reasons
- risk_or_warning_words_without_positive_predicate
- clinical review status
- pending
- content role
- risk_or_warning
- context span
- end
- 442
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE PRILOSEC is a proton pump inhibitor (PPI) indicated for the: • Treatment of active duodenal ulcer in adults ( 1.1 ) • Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults ( 1.2 ) • Treatment of active benign gastric ulcer in adults ( 1.3 ) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 1 year of age and older ( 1.4 ) • Treatment of erosive esoph
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 0
- current approval status
- not_reconciled
- duplicate text group
- dup-4bbcc63162755cd9f5d6
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OMEPRAZOLE MAGNESIUM
- id
- ind-span-e062d09123513fd58f89
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- r pylori to reduce the risk of duodenal ulcer recurrence in adults ( 1.2 )
- kind
- age
- polarity
- not_inferred
- span
- end
- 234
- end exclusive
- true
- exact text
- adults
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 228
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 242
- end exclusive
- true
- exact text
- • Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults ( 1.2 )
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 140
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22296db0e8-af6e-4053-874d-2a7c8f7aba50%22
- spl effective date
- 2024-03-19
- spl set id
- b6761f84-53ac-4745-a8c8-1e5427d7e179
- spl version
- 8
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 4 · unclassified context
- application numbers
- NDA022056
- brand names
- Prilosec
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 503
- end exclusive
- true
- exact text
- n pump inhibitor (PPI) indicated for the: • Treatment of active duodenal ulcer in adults ( 1.1 ) • Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults ( 1.2 ) • Treatment of active benign gastric ulcer in adults ( 1.3 ) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 1 year of age and older ( 1.4 ) • Treatment of erosive esophagitis (EE) due to acid-mediated GERD in patients 1 month of
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 43
- current approval status
- not_reconciled
- duplicate text group
- dup-dbdbf96d7ac5eded9375
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OMEPRAZOLE MAGNESIUM
- id
- ind-span-029f24fabde2aa79033a
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • Treatment of active benign gastric ulcer in adults ( 1.3 )
- kind
- age
- polarity
- not_inferred
- span
- end
- 295
- end exclusive
- true
- exact text
- adults
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 289
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 303
- end exclusive
- true
- exact text
- • Treatment of active benign gastric ulcer in adults ( 1.3 )
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 243
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22296db0e8-af6e-4053-874d-2a7c8f7aba50%22
- spl effective date
- 2024-03-19
- spl set id
- b6761f84-53ac-4745-a8c8-1e5427d7e179
- spl version
- 8
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 5 · unclassified context
- application numbers
- NDA022056
- brand names
- Prilosec
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 613
- end exclusive
- true
- exact text
- ve duodenal ulcer in adults ( 1.1 ) • Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults ( 1.2 ) • Treatment of active benign gastric ulcer in adults ( 1.3 ) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 1 year of age and older ( 1.4 ) • Treatment of erosive esophagitis (EE) due to acid-mediated GERD in patients 1 month of age and older ( 1.5 ) • Maintenance of healing of EE due to acid-mediated GERD in patients 1 year of age and o
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 104
- current approval status
- not_reconciled
- duplicate text group
- dup-3706b5d7870019ed1218
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OMEPRAZOLE MAGNESIUM
- id
- ind-span-f78a32ec6c380b62cc90
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 413
- end exclusive
- true
- exact text
- • Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 1 year of age and older ( 1.4 )
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 304
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22296db0e8-af6e-4053-874d-2a7c8f7aba50%22
- spl effective date
- 2024-03-19
- spl set id
- b6761f84-53ac-4745-a8c8-1e5427d7e179
- spl version
- 8
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 6 · unclassified context
- application numbers
- NDA022056
- brand names
- Prilosec
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 724
- end exclusive
- true
- exact text
- recurrence in adults ( 1.2 ) • Treatment of active benign gastric ulcer in adults ( 1.3 ) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 1 year of age and older ( 1.4 ) • Treatment of erosive esophagitis (EE) due to acid-mediated GERD in patients 1 month of age and older ( 1.5 ) • Maintenance of healing of EE due to acid-mediated GERD in patients 1 year of age and older ( 1.6 ) • Pathologic hypersecretory conditions in adults ( 1.7 ) 1.1 Treatment of Active Duodenal Ulcer PR
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 214
- current approval status
- not_reconciled
- duplicate text group
- dup-92587c9d829509340d1f
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OMEPRAZOLE MAGNESIUM
- id
- ind-span-3e7616dea0f3d3733677
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 524
- end exclusive
- true
- exact text
- • Treatment of erosive esophagitis (EE) due to acid-mediated GERD in patients 1 month of age and older ( 1.5 )
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 414
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22296db0e8-af6e-4053-874d-2a7c8f7aba50%22
- spl effective date
- 2024-03-19
- spl set id
- b6761f84-53ac-4745-a8c8-1e5427d7e179
- spl version
- 8
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 7 · unclassified context
- application numbers
- NDA022056
- brand names
- Prilosec
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 825
- end exclusive
- true
- exact text
- matic gastroesophageal reflux disease (GERD) in patients 1 year of age and older ( 1.4 ) • Treatment of erosive esophagitis (EE) due to acid-mediated GERD in patients 1 month of age and older ( 1.5 ) • Maintenance of healing of EE due to acid-mediated GERD in patients 1 year of age and older ( 1.6 ) • Pathologic hypersecretory conditions in adults ( 1.7 ) 1.1 Treatment of Active Duodenal Ulcer PRILOSEC is indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal w
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 325
- current approval status
- not_reconciled
- duplicate text group
- dup-5a5089130acdeef7aa10
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OMEPRAZOLE MAGNESIUM
- id
- ind-span-da8d72ac2d086cca09ac
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 625
- end exclusive
- true
- exact text
- • Maintenance of healing of EE due to acid-mediated GERD in patients 1 year of age and older ( 1.6 )
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 525
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22296db0e8-af6e-4053-874d-2a7c8f7aba50%22
- spl effective date
- 2024-03-19
- spl set id
- b6761f84-53ac-4745-a8c8-1e5427d7e179
- spl version
- 8
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 8 · unclassified context
- application numbers
- NDA022056
- brand names
- Prilosec
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 882
- end exclusive
- true
- exact text
- of erosive esophagitis (EE) due to acid-mediated GERD in patients 1 month of age and older ( 1.5 ) • Maintenance of healing of EE due to acid-mediated GERD in patients 1 year of age and older ( 1.6 ) • Pathologic hypersecretory conditions in adults ( 1.7 ) 1.1 Treatment of Active Duodenal Ulcer PRILOSEC is indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 426
- current approval status
- not_reconciled
- duplicate text group
- dup-386ad9dfaba4cf40861a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OMEPRAZOLE MAGNESIUM
- id
- ind-span-3861fe008b2724897a09
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • Pathologic hypersecretory conditions in adults ( 1.7 )
- kind
- age
- polarity
- not_inferred
- span
- end
- 674
- end exclusive
- true
- exact text
- adults
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 668
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 682
- end exclusive
- true
- exact text
- • Pathologic hypersecretory conditions in adults ( 1.7 )
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 626
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22296db0e8-af6e-4053-874d-2a7c8f7aba50%22
- spl effective date
- 2024-03-19
- spl set id
- b6761f84-53ac-4745-a8c8-1e5427d7e179
- spl version
- 8
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 9 · positive indication candidate
- application numbers
- NDA022056
- brand names
- Prilosec
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 1004
- end exclusive
- true
- exact text
- patients 1 month of age and older ( 1.5 ) • Maintenance of healing of EE due to acid-mediated GERD in patients 1 year of age and older ( 1.6 ) • Pathologic hypersecretory conditions in adults ( 1.7 ) 1.1 Treatment of Active Duodenal Ulcer PRILOSEC is indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 483
- current approval status
- not_reconciled
- duplicate text group
- dup-5951f372894515a3ce8a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OMEPRAZOLE MAGNESIUM
- id
- ind-span-4cdefab38b81d60a595f
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- positive predicate support span
- end
- 743
- end exclusive
- true
- exact text
- is indicated
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 731
- qualifier mentions
- context exact
- icated for short-term treatment of active duodenal ulcer in adults.
- kind
- age
- polarity
- not_inferred
- span
- end
- 803
- end exclusive
- true
- exact text
- adults
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 797
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 804
- end exclusive
- true
- exact text
- 1.1 Treatment of Active Duodenal Ulcer PRILOSEC is indicated for short-term treatment of active duodenal ulcer in adults.
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 683
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22296db0e8-af6e-4053-874d-2a7c8f7aba50%22
- spl effective date
- 2024-03-19
- spl set id
- b6761f84-53ac-4745-a8c8-1e5427d7e179
- spl version
- 8
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 10 · unclassified context
- application numbers
- NDA022056
- brand names
- Prilosec
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1042
- end exclusive
- true
- exact text
- ge and older ( 1.6 ) • Pathologic hypersecretory conditions in adults ( 1.7 ) 1.1 Treatment of Active Duodenal Ulcer PRILOSEC is indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce th
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 605
- current approval status
- not_reconciled
- duplicate text group
- dup-4871a5347678ea3b9900
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OMEPRAZOLE MAGNESIUM
- id
- ind-span-51c0364a304c45d5c30d
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 842
- end exclusive
- true
- exact text
- Most patients heal within four weeks.
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 805
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22296db0e8-af6e-4053-874d-2a7c8f7aba50%22
- spl effective date
- 2024-03-19
- spl set id
- b6761f84-53ac-4745-a8c8-1e5427d7e179
- spl version
- 8
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 11 · unclassified context
- application numbers
- NDA022056
- brand names
- Prilosec
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1105
- end exclusive
- true
- exact text
- rsecretory conditions in adults ( 1.7 ) 1.1 Treatment of Active Duodenal Ulcer PRILOSEC is indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy PRILOSEC in
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 643
- current approval status
- not_reconciled
- duplicate text group
- dup-17b9b5810de033f09216
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OMEPRAZOLE MAGNESIUM
- id
- ind-span-4ca3cf1b1d1c1bf01e62
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 905
- end exclusive
- true
- exact text
- Some patients may require an additional four weeks of therapy.
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 843
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22296db0e8-af6e-4053-874d-2a7c8f7aba50%22
- spl effective date
- 2024-03-19
- spl set id
- b6761f84-53ac-4745-a8c8-1e5427d7e179
- spl version
- 8
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 12 · risk or warning
- application numbers
- NDA022056
- brand names
- Prilosec
- classification reasons
- risk_or_warning_words_without_positive_predicate
- clinical review status
- pending
- content role
- risk_or_warning
- context span
- end
- 1278
- end exclusive
- true
- exact text
- Duodenal Ulcer PRILOSEC is indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy PRILOSEC in combination with clarithromycin and amoxicillin, is indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history)
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 706
- current approval status
- not_reconciled
- duplicate text group
- dup-37e56b17497f132eb64b
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OMEPRAZOLE MAGNESIUM
- id
- ind-span-69b4ae9fc5124bd826bd
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 1078
- end exclusive
- true
- exact text
- 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 906
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22296db0e8-af6e-4053-874d-2a7c8f7aba50%22
- spl effective date
- 2024-03-19
- spl set id
- b6761f84-53ac-4745-a8c8-1e5427d7e179
- spl version
- 8
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 13 · positive indication candidate
- application numbers
- NDA022056
- brand names
- Prilosec
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 1512
- end exclusive
- true
- exact text
- nal four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy PRILOSEC in combination with clarithromycin and amoxicillin, is indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy PRILOSEC in combination with clarithromycin is indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients wh
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 879
- current approval status
- not_reconciled
- duplicate text group
- dup-6171852301e896f0300c
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OMEPRAZOLE MAGNESIUM
- id
- ind-span-f38ea1ab1fbeb8d0d859
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- positive predicate support span
- end
- 1167
- end exclusive
- true
- exact text
- is indicated
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 1155
- qualifier mentions
- context exact
- (active or up to 1-year history) to eradicate H. pylori in adults.
- kind
- age
- polarity
- not_inferred
- span
- end
- 1311
- end exclusive
- true
- exact text
- adults
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 1305
- context exact
- Triple Therapy PRILOSEC in combination with clarithromycin and amoxicillin, is indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 1200
- end exclusive
- true
- exact text
- in combination with clarithromycin and amoxicillin, is indicated for treatment of patients with H
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 1103
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 1312
- end exclusive
- true
- exact text
- Triple Therapy PRILOSEC in combination with clarithromycin and amoxicillin, is indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults.
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 1079
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22296db0e8-af6e-4053-874d-2a7c8f7aba50%22
- spl effective date
- 2024-03-19
- spl set id
- b6761f84-53ac-4745-a8c8-1e5427d7e179
- spl version
- 8
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 14 · positive indication candidate
- application numbers
- NDA022056
- brand names
- Prilosec
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 1694
- end exclusive
- true
- exact text
- tion with clarithromycin and amoxicillin, is indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy PRILOSEC in combination with clarithromycin is indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, PRILOSEC with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail t
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 1113
- current approval status
- not_reconciled
- duplicate text group
- dup-fd3a02e5f3882d9ae23c
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OMEPRAZOLE MAGNESIUM
- id
- ind-span-5e7b02d00081c5ea2a88
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- positive predicate support span
- end
- 1382
- end exclusive
- true
- exact text
- is indicated
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 1370
- qualifier mentions
- context exact
- ection and duodenal ulcer disease to eradicate H. pylori in adults.
- kind
- age
- polarity
- not_inferred
- span
- end
- 1493
- end exclusive
- true
- exact text
- adults
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 1487
- context exact
- Dual Therapy PRILOSEC in combination with clarithromycin is indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 1415
- end exclusive
- true
- exact text
- in combination with clarithromycin is indicated for treatment of patients with H
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 1335
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 1494
- end exclusive
- true
- exact text
- Dual Therapy PRILOSEC in combination with clarithromycin is indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults.
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 1313
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22296db0e8-af6e-4053-874d-2a7c8f7aba50%22
- spl effective date
- 2024-03-19
- spl set id
- b6761f84-53ac-4745-a8c8-1e5427d7e179
- spl version
- 8
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 15 · unclassified context
- application numbers
- NDA022056
- brand names
- Prilosec
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1871
- end exclusive
- true
- exact text
- pylori in adults. Dual Therapy PRILOSEC in combination with clarithromycin is indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, PRILOSEC with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy shoul
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 1295
- current approval status
- not_reconciled
- duplicate text group
- dup-741b6638576e83a44bb9
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OMEPRAZOLE MAGNESIUM
- id
- ind-span-974f73b1cc70a8fe3685
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 1671
- end exclusive
- true
- exact text
- Among patients who fail therapy, PRILOSEC with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy.
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 1495
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22296db0e8-af6e-4053-874d-2a7c8f7aba50%22
- spl effective date
- 2024-03-19
- spl set id
- b6761f84-53ac-4745-a8c8-1e5427d7e179
- spl version
- 8
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 16 · unclassified context
- application numbers
- NDA022056
- brand names
- Prilosec
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1940
- end exclusive
- true
- exact text
- e H. pylori in adults. Among patients who fail therapy, PRILOSEC with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology ( 12.4 ) and the clarithro
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 1472
- current approval status
- not_reconciled
- duplicate text group
- dup-0756ae3823798c4a0296
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OMEPRAZOLE MAGNESIUM
- id
- ind-span-436c738d208f8bfeb39b
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 1740
- end exclusive
- true
- exact text
- In patients who fail therapy, susceptibility testing should be done.
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 1672
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22296db0e8-af6e-4053-874d-2a7c8f7aba50%22
- spl effective date
- 2024-03-19
- spl set id
- b6761f84-53ac-4745-a8c8-1e5427d7e179
- spl version
- 8
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 17 · unclassified context
- application numbers
- NDA022056
- brand names
- Prilosec
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2195
- end exclusive
- true
- exact text
- clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology ( 12.4 ) and the clarithromycin prescribing information, Microbiology section ] . 1.3 Treatment of Active Benign Gastric Ulcer PRILOSEC is indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer in adults. 1.4 Treatment of Symptomatic Gastroesophageal Refl
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 1541
- current approval status
- not_reconciled
- duplicate text group
- dup-ffe2b59b99940f6a1487
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OMEPRAZOLE MAGNESIUM
- id
- ind-span-da01fb7636ad0f3336bc
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 1995
- end exclusive
- true
- exact text
- If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology ( 12.4 ) and the clarithromycin prescribing information, Microbiology section ] .
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 1741
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22296db0e8-af6e-4053-874d-2a7c8f7aba50%22
- spl effective date
- 2024-03-19
- spl set id
- b6761f84-53ac-4745-a8c8-1e5427d7e179
- spl version
- 8
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 18 · positive indication candidate
- application numbers
- NDA022056
- brand names
- Prilosec
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 2344
- end exclusive
- true
- exact text
- eptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology ( 12.4 ) and the clarithromycin prescribing information, Microbiology section ] . 1.3 Treatment of Active Benign Gastric Ulcer PRILOSEC is indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer in adults. 1.4 Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD) PRILOSEC is indicated for the treatment of heartburn and other symptoms associated with GERD for up to 4 weeks in patients 1 year o
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 1796
- current approval status
- not_reconciled
- duplicate text group
- dup-529c7203cfb6193f0f00
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OMEPRAZOLE MAGNESIUM
- id
- ind-span-54c60fe530f6c20bd980
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- positive predicate support span
- end
- 2062
- end exclusive
- true
- exact text
- is indicated
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 2050
- qualifier mentions
- context exact
- treatment (4 to 8 weeks) of active benign gastric ulcer in adults.
- kind
- age
- polarity
- not_inferred
- span
- end
- 2143
- end exclusive
- true
- exact text
- adults
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 2137
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 2144
- end exclusive
- true
- exact text
- 1.3 Treatment of Active Benign Gastric Ulcer PRILOSEC is indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer in adults.
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 1996
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22296db0e8-af6e-4053-874d-2a7c8f7aba50%22
- spl effective date
- 2024-03-19
- spl set id
- b6761f84-53ac-4745-a8c8-1e5427d7e179
- spl version
- 8
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 19 · positive indication candidate
- application numbers
- NDA022056
- brand names
- Prilosec
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 2560
- end exclusive
- true
- exact text
- prescribing information, Microbiology section ] . 1.3 Treatment of Active Benign Gastric Ulcer PRILOSEC is indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer in adults. 1.4 Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD) PRILOSEC is indicated for the treatment of heartburn and other symptoms associated with GERD for up to 4 weeks in patients 1 year of age and older. 1.5 Treatment of Erosive Esophagitis (EE) Due to Acid-Mediated GERD Pediatric Patients 1 Year of Age to Adults PRILOSEC is indicated for the short-term treatment (4 to 8 weeks) of EE due to acid-medi
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 1945
- current approval status
- not_reconciled
- duplicate text group
- dup-d4a2d62dff637c059a61
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OMEPRAZOLE MAGNESIUM
- id
- ind-span-c6205f33c97a00727c27
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- positive predicate support span
- end
- 2234
- end exclusive
- true
- exact text
- is indicated
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 2222
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 2360
- end exclusive
- true
- exact text
- 1.4 Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD) PRILOSEC is indicated for the treatment of heartburn and other symptoms associated with GERD for up to 4 weeks in patients 1 year of age and older.
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 2145
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22296db0e8-af6e-4053-874d-2a7c8f7aba50%22
- spl effective date
- 2024-03-19
- spl set id
- b6761f84-53ac-4745-a8c8-1e5427d7e179
- spl version
- 8
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 20 · positive indication candidate
- application numbers
- NDA022056
- brand names
- Prilosec
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 2843
- end exclusive
- true
- exact text
- Symptomatic Gastroesophageal Reflux Disease (GERD) PRILOSEC is indicated for the treatment of heartburn and other symptoms associated with GERD for up to 4 weeks in patients 1 year of age and older. 1.5 Treatment of Erosive Esophagitis (EE) Due to Acid-Mediated GERD Pediatric Patients 1 Year of Age to Adults PRILOSEC is indicated for the short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD that has been diagnosed by endoscopy in patients 1 year of age and older. The efficacy of PRILOSEC used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be gi
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 2161
- current approval status
- not_reconciled
- duplicate text group
- dup-f82d2f8b3420f981fbe7
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OMEPRAZOLE MAGNESIUM
- id
- ind-span-159298fffeed5ebf5968
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- positive predicate support span
- end
- 2493
- end exclusive
- true
- exact text
- is indicated
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 2481
- qualifier mentions
- context exact
- tment of Erosive Esophagitis (EE) Due to Acid-Mediated GERD Pediatric Patients 1 Year of Age to Adults PRILOSEC is indicated for the short
- kind
- age
- polarity
- not_inferred
- span
- end
- 2447
- end exclusive
- true
- exact text
- Pediatric Patients
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 2429
- context exact
- e to Acid-Mediated GERD Pediatric Patients 1 Year of Age to Adults PRILOSEC is indicated for the short-term treatment (4 to 8
- kind
- age
- polarity
- not_inferred
- span
- end
- 2471
- end exclusive
- true
- exact text
- Adults
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 2465
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 2643
- end exclusive
- true
- exact text
- 1.5 Treatment of Erosive Esophagitis (EE) Due to Acid-Mediated GERD Pediatric Patients 1 Year of Age to Adults PRILOSEC is indicated for the short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD that has been diagnosed by endoscopy in patients 1 year of age and older.
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 2361
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22296db0e8-af6e-4053-874d-2a7c8f7aba50%22
- spl effective date
- 2024-03-19
- spl set id
- b6761f84-53ac-4745-a8c8-1e5427d7e179
- spl version
- 8
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 21 · limitation of use
- application numbers
- NDA022056
- brand names
- Prilosec
- classification reasons
- negative_or_not_established_clause
- clinical review status
- pending
- content role
- limitation_of_use
- context span
- end
- 2943
- end exclusive
- true
- exact text
- nts 1 Year of Age to Adults PRILOSEC is indicated for the short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD that has been diagnosed by endoscopy in patients 1 year of age and older. The efficacy of PRILOSEC used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 2444
- current approval status
- not_reconciled
- duplicate text group
- dup-d41fd19a017391037c18
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OMEPRAZOLE MAGNESIUM
- id
- ind-span-12fcbc4fe1484e0ab5dc
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 2743
- end exclusive
- true
- exact text
- The efficacy of PRILOSEC used for longer than 8 weeks in patients with EE has not been established.
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 2644
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22296db0e8-af6e-4053-874d-2a7c8f7aba50%22
- spl effective date
- 2024-03-19
- spl set id
- b6761f84-53ac-4745-a8c8-1e5427d7e179
- spl version
- 8
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 22 · unclassified context
- application numbers
- NDA022056
- brand names
- Prilosec
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3047
- end exclusive
- true
- exact text
- due to acid-mediated GERD that has been diagnosed by endoscopy in patients 1 year of age and older. The efficacy of PRILOSEC used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of PRILOSEC may be considered. Pediatric Patients 1 Month to Less than 1 Year of Age PRILOSEC is indica
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 2544
- current approval status
- not_reconciled
- duplicate text group
- dup-cc8c2797b71eb266edd3
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OMEPRAZOLE MAGNESIUM
- id
- ind-span-568533a8bcad5396a0d2
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 2847
- end exclusive
- true
- exact text
- If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given.
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 2744
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22296db0e8-af6e-4053-874d-2a7c8f7aba50%22
- spl effective date
- 2024-03-19
- spl set id
- b6761f84-53ac-4745-a8c8-1e5427d7e179
- spl version
- 8
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 23 · unclassified context
- application numbers
- NDA022056
- brand names
- Prilosec
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3174
- end exclusive
- true
- exact text
- efficacy of PRILOSEC used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of PRILOSEC may be considered. Pediatric Patients 1 Month to Less than 1 Year of Age PRILOSEC is indicated for the short-term treatment (up to 6 weeks) of EE due to acid-mediated GERD in pediatric patients 1 month to less than 1 y
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 2648
- current approval status
- not_reconciled
- duplicate text group
- dup-5ae0f42b06c51428ece6
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OMEPRAZOLE MAGNESIUM
- id
- ind-span-50749f2e038570350b1d
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 2974
- end exclusive
- true
- exact text
- If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of PRILOSEC may be considered.
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 2848
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22296db0e8-af6e-4053-874d-2a7c8f7aba50%22
- spl effective date
- 2024-03-19
- spl set id
- b6761f84-53ac-4745-a8c8-1e5427d7e179
- spl version
- 8
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 24 · positive indication candidate
- application numbers
- NDA022056
- brand names
- Prilosec
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 3385
- end exclusive
- true
- exact text
- o 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of PRILOSEC may be considered. Pediatric Patients 1 Month to Less than 1 Year of Age PRILOSEC is indicated for the short-term treatment (up to 6 weeks) of EE due to acid-mediated GERD in pediatric patients 1 month to less than 1 year of age. 1.6 Maintenance of Healing of EE Due to Acid-Mediated GERD PRILOSEC is indicated for the maintenance healing of EE due to acid-mediated GERD in patients 1 year of age and older. Controlled studies do
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 2775
- current approval status
- not_reconciled
- duplicate text group
- dup-742fbe1ef0fb6194221c
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OMEPRAZOLE MAGNESIUM
- id
- ind-span-bc8ab3cbdfda2d34b8b9
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- positive predicate support span
- end
- 3050
- end exclusive
- true
- exact text
- is indicated
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 3038
- qualifier mentions
- context exact
- Pediatric Patients 1 Month to Less than 1 Year of Age PRILOSEC is indicated fo
- kind
- age
- polarity
- not_inferred
- span
- end
- 2993
- end exclusive
- true
- exact text
- Pediatric Patients
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 2975
- context exact
- reatment (up to 6 weeks) of EE due to acid-mediated GERD in pediatric patients 1 month to less than 1 year of age.
- kind
- age
- polarity
- not_inferred
- span
- end
- 3149
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 3131
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 3185
- end exclusive
- true
- exact text
- Pediatric Patients 1 Month to Less than 1 Year of Age PRILOSEC is indicated for the short-term treatment (up to 6 weeks) of EE due to acid-mediated GERD in pediatric patients 1 month to less than 1 year of age.
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 2975
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22296db0e8-af6e-4053-874d-2a7c8f7aba50%22
- spl effective date
- 2024-03-19
- spl set id
- b6761f84-53ac-4745-a8c8-1e5427d7e179
- spl version
- 8
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 25 · positive indication candidate
- application numbers
- NDA022056
- brand names
- Prilosec
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 3563
- end exclusive
- true
- exact text
- atients 1 Month to Less than 1 Year of Age PRILOSEC is indicated for the short-term treatment (up to 6 weeks) of EE due to acid-mediated GERD in pediatric patients 1 month to less than 1 year of age. 1.6 Maintenance of Healing of EE Due to Acid-Mediated GERD PRILOSEC is indicated for the maintenance healing of EE due to acid-mediated GERD in patients 1 year of age and older. Controlled studies do not extend beyond 12 months. 1.7 Pathological Hypersecretory Conditions PRILOSEC is indicated for the long-term treatment of pathological hypersecretory conditions (e.g., Zollin
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 2986
- current approval status
- not_reconciled
- duplicate text group
- dup-76b4ddb835f3127b93d2
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OMEPRAZOLE MAGNESIUM
- id
- ind-span-9035cfbd899972e6bb45
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- positive predicate support span
- end
- 3266
- end exclusive
- true
- exact text
- is indicated
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 3254
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 3363
- end exclusive
- true
- exact text
- 1.6 Maintenance of Healing of EE Due to Acid-Mediated GERD PRILOSEC is indicated for the maintenance healing of EE due to acid-mediated GERD in patients 1 year of age and older.
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 3186
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22296db0e8-af6e-4053-874d-2a7c8f7aba50%22
- spl effective date
- 2024-03-19
- spl set id
- b6761f84-53ac-4745-a8c8-1e5427d7e179
- spl version
- 8
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 26 · unclassified context
- application numbers
- NDA022056
- brand names
- Prilosec
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3614
- end exclusive
- true
- exact text
- s than 1 year of age. 1.6 Maintenance of Healing of EE Due to Acid-Mediated GERD PRILOSEC is indicated for the maintenance healing of EE due to acid-mediated GERD in patients 1 year of age and older. Controlled studies do not extend beyond 12 months. 1.7 Pathological Hypersecretory Conditions PRILOSEC is indicated for the long-term treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine adenomas a
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 3164
- current approval status
- not_reconciled
- duplicate text group
- dup-cd100b5536e30ab6b8f2
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OMEPRAZOLE MAGNESIUM
- id
- ind-span-704e2463c6b30253e497
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 3414
- end exclusive
- true
- exact text
- Controlled studies do not extend beyond 12 months.
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 3364
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22296db0e8-af6e-4053-874d-2a7c8f7aba50%22
- spl effective date
- 2024-03-19
- spl set id
- b6761f84-53ac-4745-a8c8-1e5427d7e179
- spl version
- 8
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 27 · positive indication candidate
- application numbers
- NDA022056
- brand names
- Prilosec
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 3650
- end exclusive
- true
- exact text
- EE Due to Acid-Mediated GERD PRILOSEC is indicated for the maintenance healing of EE due to acid-mediated GERD in patients 1 year of age and older. Controlled studies do not extend beyond 12 months. 1.7 Pathological Hypersecretory Conditions PRILOSEC is indicated for the long-term treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis) in adults.
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 3215
- current approval status
- not_reconciled
- duplicate text group
- dup-f9a810dee0def53a29b0
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OMEPRAZOLE MAGNESIUM
- id
- ind-span-04ee9986d372b2e7e0c3
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- positive predicate support span
- end
- 3479
- end exclusive
- true
- exact text
- is indicated
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 3467
- qualifier mentions
- context exact
- , multiple endocrine adenomas and systemic mastocytosis) in adults.
- kind
- age
- polarity
- not_inferred
- span
- end
- 3649
- end exclusive
- true
- exact text
- adults
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 3643
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 3650
- end exclusive
- true
- exact text
- 1.7 Pathological Hypersecretory Conditions PRILOSEC is indicated for the long-term treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis) in adults.
- label id
- 296db0e8-af6e-4053-874d-2a7c8f7aba50
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- cb7432d9e9e325b4f7a5ebbc34eca3851ae5eb32ebe7ca87a006beb29b956848
- start
- 3415
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22296db0e8-af6e-4053-874d-2a7c8f7aba50%22
- spl effective date
- 2024-03-19
- spl set id
- b6761f84-53ac-4745-a8c8-1e5427d7e179
- spl version
- 8
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Preserved source evidence · Not medical advice